ENANTA PHARMACEUTICALS, INC Investment Income, Net
ENANTA PHARMACEUTICALS, INC (ENTA) reported Investment Income, Net of $1.90 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeNet · last filed 2026-08-12
- ENANTA PHARMACEUTICALS, INC investment income, net for the quarter ending 2026-06-30 was $1.90M, a 16.81% decline year-over-year.
- ENANTA PHARMACEUTICALS, INC investment income, net for the quarter ending 2026-03-31 was $2.08M, a 9.08% decline year-over-year.
- ENANTA PHARMACEUTICALS, INC investment income, net for the quarter ending 2025-12-31 was $2.42M, a 13.47% decline year-over-year.
- ENANTA PHARMACEUTICALS, INC investment income, net for the quarter ending 2025-09-30 was $2.07M, a 34.95% decline year-over-year.
- ENANTA PHARMACEUTICALS, INC investment income, net for fiscal 2025 was $9.44M, a 36.07% decline from fiscal 2024.
- ENANTA PHARMACEUTICALS, INC investment income, net for fiscal 2024 was $14.77M, a 30.02% increase from fiscal 2023.
- ENANTA PHARMACEUTICALS, INC investment income, net for fiscal 2023 was $11.36M, a 622.19% increase from fiscal 2022.
- ENANTA PHARMACEUTICALS, INC investment income, net for fiscal 2022 was $1.57M.
| Period end | Investment Income, Net 3 month | Investment Income, Net 6 month | Investment Income, Net 9 month | Investment Income, Net 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.90M 10-Q · filed 2026-08-12 | $3.98M derived: sum of 2 quarters · filed 2026-08-12 | $6.41M 10-Q · filed 2026-08-12 | $8.47M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $2.08M 10-Q · filed 2026-05-13 | $4.51M 10-Q · filed 2026-05-13 | $6.57M derived: sum of 3 quarters · filed 2026-05-13 | $8.86M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $2.42M 10-Q · filed 2026-02-11 | $4.49M derived: sum of 2 quarters · filed 2026-02-11 | $6.77M derived: sum of 3 quarters · filed 2026-08-12 | $9.06M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-09-30 | $2.07M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-19 | $4.35M derived: sum of 2 quarters · filed 2026-08-12 | $6.64M derived: sum of 3 quarters · filed 2026-08-12 | $9.44M 10-K · filed 2025-11-19 |
| 2025-06-30 | $2.29M 10-Q · filed 2026-08-12 | $4.58M derived: sum of 2 quarters · filed 2026-08-12 | $7.38M 10-Q · filed 2026-08-12 | $10.55M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $2.29M 10-Q · filed 2026-05-13 | $5.09M 10-Q · filed 2026-05-13 | $8.27M derived: sum of 3 quarters · filed 2026-05-13 | $11.75M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $2.80M 10-Q · filed 2026-02-11 | $5.97M derived: sum of 2 quarters · filed 2026-02-11 | $9.46M derived: sum of 3 quarters · filed 2026-02-11 | $13.27M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-09-30 | $3.18M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-19 | $6.66M derived: sum of 2 quarters · filed 2025-11-19 | $10.47M derived: sum of 3 quarters · filed 2025-11-19 | $14.77M 10-K · filed 2025-11-19 |
| 2024-06-30 | $3.49M 10-Q · filed 2025-08-13 | $7.30M derived: sum of 2 quarters · filed 2025-08-13 | $11.59M 10-Q · filed 2025-08-13 | |
| 2024-03-31 | $3.81M 10-Q · filed 2025-05-14 | $8.11M 10-Q · filed 2025-05-14 | ||
| 2023-12-31 | $4.30M 10-Q · filed 2025-02-12 | |||
| 2023-09-30 | $11.36M 10-K · filed 2025-11-19 | |||
| 2022-09-30 | $1.57M 10-K · filed 2024-11-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |